Search Results for "RNAi"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Patient Demographics and clinical characteristics at enrolment in ELEVATE, an international registry of Acute Hepatic Porphyria

Enrollment Characteristics and Real-World Insights Into Disease Burden and Givosiran Treatment in Patients With Acute Hepatic Porphyria in the ELEVATE Registry

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy

This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Targeting Cerebral Amyloid Angiopathy at its Source: An Amyloid Beta Precursor Protein-Targeted siRNA Reduced Vascular Amyloid Beta and Hemorrhage in Rodent Models

HELIOS-B Plain Language Summary

This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)

Zilebesiran: Phase 2 Studies

Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.

Givosiran: Pregnancy and Lactation

Standard response letter on givosiran and its use in pregnant or lactating patients.

Phase 3 HELIOS-B Study Rationale

This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.

Nucresiran: Phase 1 Study

Standard response letter on the phase 1 study of nucresiran.

Vutrisiran: Use with mRNA COVID-19 Vaccines

Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

Zilebesiran: KARDIA-1 Study

Standard response letter on zilebesiran and the KARDIA-1 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran dosing regimens for adults with mild to moderate hypertension.

Vutrisiran: Technetium Scintigraphy

Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.

Givosiran: Pancreatitis

Standard response letter on givosiran and the adverse event of pancreatitis.

Givosiran: Timing of Dosing

Standard response letter on the timing of dosing of givosiran in the Phase 1 study.

Zilebesiran: Phase 1 Study Overview

Standard response letter on the phase 1 study of zilebesiran, a study evaluating the safety, PK , PD, as well as exploratory antihypertensive efficacy of zilebesiran in patients with hypertension.

Vutrisiran: Cross-Reactivity with Patisiran

Standard response letter on the cross-reactivity between vutrisiran and patisiran.

Insights from the HELIOS-A Study

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

Lumasiran: Use in Kidney Transplantation

Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.

Givosiran: Hepatic Effects

Standard response letter on hepatic effects observed with the use of givosiran.

Zilebesiran: KARDIA-3 Study

Standard response letter on zilebesiran and the KARDIA-3 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran in patients with high CV risk and hypertension that is not adequately controlled with at least 2 standard-of-care antihypertensives.

Lumasiran: Mechanism of Action

Standard response letter on the mechanism of action of lumasiran.

HELIOS-A: 18-month randomised treatment extension analysis of vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Vutrisiran: Impact on Thyroid Function

Standard response letter on vutrisiran and thyroid function.

Zilebesiran: ZENITH Study

Standard response letter on zilebesiran and the ZENITH study, a phase 3 cardiovascular outcomes trial.

Mivelsiran: cAPPricorn-1 Study

Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "RNAi"

Patient Demographics and clinical characteristics at enrolment in ELEVATE, an international registry of Acute Hepatic Porphyria

Enrollment Characteristics and Real-World Insights Into Disease Burden and Givosiran Treatment in Patients With Acute Hepatic Porphyria in the ELEVATE Registry

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Targeting Cerebral Amyloid Angiopathy at its Source: An Amyloid Beta Precursor Protein-Targeted siRNA Reduced Vascular Amyloid Beta and Hemorrhage in Rodent Models

HELIOS-B Plain Language Summary This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)

Zilebesiran: Phase 2 Studies Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.

Givosiran: Pregnancy and Lactation Standard response letter on givosiran and its use in pregnant or lactating patients.

Phase 3 HELIOS-B Study Rationale This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.

Nucresiran: Phase 1 Study Standard response letter on the phase 1 study of nucresiran.

Vutrisiran: Use with mRNA COVID-19 Vaccines Standard response letter on use of mRNA COVID-19 vaccines in patients receiving vutrisiran.

Zilebesiran: KARDIA-1 Study Standard response letter on zilebesiran and the KARDIA-1 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran dosing regimens for adults with mild to moderate hypertension.

Vutrisiran: Technetium Scintigraphy Standard response letter on vutrisiran and technetium scintigraphy data assessed in a subset of patients from the HELIOS-A study.

Givosiran: Pancreatitis Standard response letter on givosiran and the adverse event of pancreatitis.

Givosiran: Timing of Dosing Standard response letter on the timing of dosing of givosiran in the Phase 1 study.

Zilebesiran: Phase 1 Study Overview Standard response letter on the phase 1 study of zilebesiran, a study evaluating the safety, PK , PD, as well as exploratory antihypertensive efficacy of zilebesiran in patients with hypertension.

Vutrisiran: Cross-Reactivity with Patisiran Standard response letter on the cross-reactivity between vutrisiran and patisiran.

Insights from the HELIOS-A Study This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

Lumasiran: Use in Kidney Transplantation Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.

Givosiran: Hepatic Effects Standard response letter on hepatic effects observed with the use of givosiran.

Zilebesiran: KARDIA-3 Study Standard response letter on zilebesiran and the KARDIA-3 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran in patients with high CV risk and hypertension that is not adequately controlled with at least 2 standard-of-care antihypertensives.

Lumasiran: Mechanism of Action Standard response letter on the mechanism of action of lumasiran.